News | April 16, 2025
Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The supply of these goods is set to commence within the first quarter of FY26
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Strengthening capabilities in Peptide Therapeutics and CDMO services
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Subscribe To Our Newsletter & Stay Updated
